Abstract. MicroRNAs (miRNAs) are small non-coding RNAs that inhibit gene expression by cleaving or hindering the translation of target mRNAs. We used microarray-based comparative transcriptome analysis to identify changes in miRNA expression and function between a human cell line, RSa, which is highly sensitive to HuIFN-β-mediated inhibition of cell viability, and its variant, the F-IF r cell line, which is relatively resistant to the cytokine. miR-431 expression was significantly higher in RSa cells compared with F-IF r cells. The addition of HuIFN-β to RSa cultures reduced cell viability, down-regulated expression of IGF1R and IRS2 (putative miR-431 target genes), and inhibited the PI3K-Akt and MAPK pathways. The survival of F-IF r cells was not reduced by HuIFN-β, but transient transfection with miR-431 precursors significantly decreased viability and concomitantly down-regulated IGF1R and IRS2 expression. In addition, the MAPK pathway, but not the PI3K-Akt pathway, was suppressed in F-IF r cells. Based on these results, we propose that, in RSa cells, HuIFN-β-induced miR-431 expression may down-regulate IGF1R and IRS2 expression, and consequently inhibit cell proliferation by suppressing the MAPK pathway.
Introduction
MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression by base pairing specifically with nucleotides in the 3' untranslated regions of target mRNAs or by directing mRNA degradation (1) . MiRNAs play important roles in cell proliferation, apoptosis, and differentiation (2, 3) . In particular, miRNAs that regulate cell proliferation have been implicated in various cancers. Numerous studies have revealed differences in the expression of various miRNAs between tumors and normal tissues (4) , suggesting that miRNAs can function as either tumor suppressors or oncogenes in human cancers. In addition, there are a number of reports demonstrating that certain miRNAs participate in the activity of various anti-cancer drugs. For example, the combination of miR-145 and 5-fluorouracil (5-FU) has an anti-tumor effect on breast cancer (5) . In a non-small cell lung cancer cell line (A549), cisplatin sensitivity was increased by up-regulating miR-451 expression (6) . In contrast, miR-21 induced resistance to the anti-cancer effects of IFN-α/5-FU combination therapy in hepatocellular carcinoma cells (7) . Human interferons (HuIFNs) are a family of cytokines that have various biological functions, including anti-viral and antitumor activity (8) . They also regulate basic cellular functions including growth, differentiation, and immune reactivity (9) (10) (11) . HuIFNs induce a cascade of events leading to an increase in the expression of various genes, including those responsible for the biological effects of IFNs (9) (10) (11) (12) (13) . HuIFNs are divided into type I, II, and III subtypes, based in part on the differential use of unique receptors through which they mediate their biological effects. HuIFN-α and -β are type I IFNs. HuIFN-β has proven useful as an anti-neoplastic drug, although the role of miRNAs in this function is not clear. In this study, we focused on the miRNAs that were induced by HuIFN-β using the HuIFN-β-sensitive cell line, RSa, and its resistant variant, the F-IF r cell line. Our aim was to identify miRNAs that are up-regulated by HuIFN-β and are responsible for suppressing cell proliferation in human cells.
Materials and methods
Cell lines and culture conditions. RSa cells were established from human embryo-derived fibroblasts by double infection with Simian virus 40 and Rous sarcoma virus. These cells are highly sensitive to the ability of HuIFN-β to inhibit cell viability. The F-IF r line is a variant with increased resistance to HuIFN-β. Both cell lines were cultured in Eagle's minimal essential medium (EMEM; Nissui, Tokyo, Japan) containing 10% calf serum (CS; Invitrogen, Carlsbad, CA, USA) at 37˚C in a humidified atmosphere containing 5% CO 2 .
RNA extraction. Total RNA was extracted using TRIzol reagent (Invitrogen) according to the manufacturer's instructions. Transfection of miRNA molecules. MiRNA precursors that mimic miR-381 or miR-431, a control non-specific miRNA (Pre-miR Negative Control), and anti-miRNA molecules were obtained from Ambion (Austin, TX, USA). Using siPORT NeoFX (Ambion), miRNA precursors were transfected into F-IF r cells and anti-miRNA molecules into RSa cells, according to the manufacturer's protocol. For siRNA transfection, cells (plated to reach 80% confluence after 12 or 24 h) were treated with siRNAs complementary to each target gene or a control using siPORT NeoFX. Predicted target genes for miRNA were identified using TargetScan (http://www.targetscan.org).
Inhibition of cell viability by human IFN
Western blotting. Cells grown to 80% confluence were treated with HuIFN-β, pre-miR-431 or anti-miR-431. After treatment, cells were washed three times with ice-cold PBS. Equal amounts of protein were separated by SDS-PAGE and transferred to polyvinylidene fluoride membranes (ATTO, Tokyo, Japan). Membranes were blocked in 5% non-fat dried milk in PBST and incubated with primary antibody. The following antibodies were used: IGF-1Rα, IGF-1Rβ, IRS2, and total Akt1/2/3 from Santa Cruz Biotechnology, Santa Cruz, CA, USA; p-Akt (phospho-Akt, Thr 308 ), p-Akt (phospho-Akt, Ser 473 ), p44/42 MAPK (Erk1/2), and phosphor-p44/42 MAPK (Erk1/2), from Cell Signaling Technology (Danvers, MA, USA). GAPDH (Sigma, St. Louis, MO, USA) was used as an internal control. Secondary antibodies were conjugated to horseradish peroxidase and immunoreactive proteins were detected using the ECL-plus system (Amersham, Piscataway, NJ, USA).
Estimation of miRNA target gene expression. Total RNA (30 ng) from F-IF r cells was reverse-transcribed using Super Script III First-Strand Synthesis SuperMix (Invitrogen) according to the manufacturer's protocol. Steady-state expression levels of IGF1R and IRS2 mRNAs were evaluated by quantitative RT-PCR using Fast SYBR Green Master Mix and the following oligonucleotide primers and annealing temperatures: IGF1R, 5'-CATCGACATCCGCAACGA-3' (forward) and 5'-CCCTCGATCACCGTGCA-3' (reverse) at 50˚C; IRS2, 5'-GT ACCTGATCGCCCTCTAC-3' (forward) and 5'-AGGCACA GACGGTACAC-3' (reverse) at 50˚C. Expression of each gene was normalized to a GAPDH control: 5'-ACCCACTCCTCCA CCTTTG-3' (forward) and 5'-CTCTTGTGCTCTTGCTGG G-3' (reverse). 
Results

Comparison of miRNA expression levels between RSa and F-IF
Effect of HuIFN-β on cell viability and miR-431 expression.
When HuIFN-β was added to culture medium at a concentration 500 IU/ml, a significant suppression of RSa cell viability was observed 24 h later (Fig. 1A) . In contrast, F-IF r cell viability was not significantly suppressed by HuIFN-β, at any dose up to 500 IU/ml, nor by any duration up to 24 h (Fig. 1B) . HuIFN-β (500 IU/ml) induced a significant increase in miR-431 expression in RSa cells relative to F-IF r cells 24 h following addition, but it did not affect miR-381 expression (Fig. 1C) .
Examination of the role of miR-431 on cell viability. In order to examine whether increased expression of miR-431 results in reduced cell viability, F-IF r cells were transiently transfected with miR-431, this resulted in a significant suppression of cell viability 24 h later ( Fig. 2A) . No significant effect on viability was observed following transfection with miR-381 ( Fig. 2A) . When RSa cells were treated with both HuIFN-β and anti-miR-431, cell proliferation was not suppressed at 24 h (Fig. 2B) .
Search for miR-431 target genes. Predicted target genes for miR-431 were identified with TargetScan (Table I) . Among these genes, we focused on the cell viability-related genes, IGF1R (insulin-like growth factor 1 receptor) and IRS2 (insulin receptor substrate 2). Schematic representation of IGF1R and IRS2 mRNAs, showing the predicted miR-431 binding sites located in their 3' UTR, are given in Fig. 3A . To determine the effects of reducing IGF1R or IRS2 mRNA levels on cell viability, we assessed the viability of F-IF r cells treated with gene-specific siRNAs or a non-targeting control siRNA. Treatment with the siRNAs led to a significant suppression of cell viability relative to control cells (Fig. 3B) .
Examination of IGF1R signaling pathways. When RSa cells were treated with HuIFN-β (500 IU/ml), a reduction in protein levels of IGF1Rα/β and IRS2 was consistently observed after 24 h (Fig. 4A) . A similar reduction was also detected in F-IF r cells transfected with miR-431 precursors (Fig. 4B) . However, 
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Gene name Total 8-mer 7-mer-m8 7-mer-1A Total 8-mer 7-mer-m8 7-mer-1A Total cont. symbol score no apparent change in protein levels was observed when F-IF r cells were treated with HuIFN-β (Fig. 4C) . HuIFN-β (500 IU/ ml) and anti-miR-431 treatment resulted in a significant increase in the expression of IGF1R and IRS2 in RSa cells (Fig. 4D) . Since IGF1R is a major player in the PI3K-Akt and MAPK signaling pathways, we investigated the effects of miR-431-mediated IGF1R down-regulation on PI3K-Akt and MAPK phosphorylation. In RSa cells, protein levels of total Akt, p-Akt Thr 308 , p-Akt Ser 473 , total Erk1/2, and p-Erk1/2 were reduced after 24 h of HuIFN-β (500 IU/ml) treatment (Fig. 5A) . In contrast, the levels of these proteins were not changed in F-IF r cells (Fig. 5B) . When F-IF r cells were transfected with miR-431 precursors, reductions in the levels of total Erk1/2 and p-Erk1/2 were observed after 24 h of transfection, while the levels of total Akt, p-Akt Thr 308 , and p-Akt Ser 473 were , total Erk1/2, and p-Erk1/2 expression in RSa cells (Fig. 5D) .
Suppression of miR-431 target genes.
Transient transfection with miR-431 precursors significantly suppressed IGF1R and IRS2 expression in F-IF r cells after 24 h relative to control-transfected cells (Fig. 6A) . Treating RSa cells with HuIFN-β (500 IU/ml) also significantly diminished IGF1R and IRS2 expression after 24 h relative to control cells (Fig. 6B) . However, when RSa cells were treated with both HuIFN-β (500 IU/ml) and anti-miR-431, IGF1R and IRS2 expression were not significantly affected (Fig. 6B) .
Effect of PI3K inhibitor on cell viability. F-IF
r cells were transfected with miR-431 precursors and/or the PI3K inhibitor LY294002. Proliferation was reduced by approximately 20% when cells were transfected with miR-431 precursors. However, it was suppressed approximately 30% when cells were transfected with miR-431 precursors and treated with LY294002 at the same time (Fig. 7) .
Discussion
There are numerous reports of the involvement of miRNAs in regulating cell proliferation in a multitude of cancer cell lines (4). We focused on a few miRNAs whose expression levels were altered by the addition of HuIFN-β in a non-cancer HuIFN-β sensitive cell line, RSa, and its variant HuIFN-β resistant cell line, F-IF r .
Based on microarray analysis, we focused on three miRNAs (miR-193b, miR-381, and miR-431) whose expression levels were up-regulated more than 5-fold in RSa cells relative to F-IF r cells. Among these, miR-381 and miR-431 were also up-regulated according to quantitative RT-PCR. In addition, HuIFN-β treatment increased miR-431 expression and reduced cell viability in RSa cells (Fig. 1A and C) . In contrast, transfection of miR-431 precursors into F-IF r cells significantly reduced cell viability (Fig. 2A) . These results suggest that miR-431 plays a role in regulating cell viability.
We then sought to determine whether miRNA-regulated signaling pathways modulated cell viability. Previous reports revealed that some signaling pathways that affect cell viability are regulated by miRNAs (14) (15) (16) (17) (18) (19) . We decided to focus on one of these -the IGF signaling pathway. The factors that activate IGF ), total Erk1/2, and p-Erk1/2 in RSa cells which were treated with HuIFN-β (500 IU/ml) and anti-miR-431 for 24 h. GAPDH was used as a loading control.
signaling pathways and promote cell proliferation in cancers have been investigated by others (20) . For numerous cancers, the activation of IGF signaling pathways contributes to cell proliferation. Therefore, the suppression of this pathway should inhibit cancer cell proliferation. In tongue squamous cell carcinoma, miR-7 levels are reduced, but the ectopic expression of miR-7 significantly down-regulates IGF1R expression, at both the mRNA and protein levels (21) . Thus, a miRNA can suppress a cell growth-signaling pathway.
In the present study, we examined the miR-431 target genes that are suspected of suppressing cell viability, and focused on IGF1R and IRS2, which are functional targets of miR-431. IGF1R is a receptor tyrosine kinase that consists of heterotetramers (α 2 β 2 ) held together by disulfide bonds, and it mediates IGF1-induced signaling. IRS2 is the main effector of the proliferative signals triggered by IGF receptors (22) . According to Western blot analysis, IGF1R and IRS2 are down-regulated in RSa cells by HuIFN-β and in F-IF r cells by transfection with miR-431 precursors (Fig. 4A and B) . These observations suggest that increased levels of miR-431 inhibit IGF1R and IRS2 expression in RSa cells. In addition, we hypothesized that miR-431-mediated IGF1R and IRS2 down-regulation would be accompanied by the inhibition of the PI3K-Akt and MAPK pathways. Indeed, HuIFN-β suppressed both signaling pathways in RSa cells (Fig. 5A) . Transfection with miR-431 precursors inhibited the MAPK pathway in F-IF r cells, although the PI3K-Akt pathway was not affected (Fig. 5C ).
There are a number of clinical reports on the therapeutic use of HuIFN-β. For example, combination therapy with HuIFN-β and Ranimustive has been particularly useful for the treatment of malignant gliomas in Japan (23) . In cases of newly diagnosed primary glioblastoma multiforme, HuIFN-β and temozolomide combination therapy is significantly associated with a favorable outcome (24) . However, there are many hurdles facing the use of HuIFN-β as an anti-cancer agent, particularly for HuIFN-β resistant cancers. For example, NC65 tumors (a human renal cell carcinoma) transfected with recombinant HuIFN-β did not shrink and failed to undergo apoptosis (25) . Thus, in clinical cases in which enhanced HuIFN-β sensitivity is desirable or in which resistance to HuIFN-β is encountered, the delivery of miR-431 precursors to the cancerous tissue, in combination with a PI3K inhibitor, may effectively suppress cancer growth.
In conclusion, our results demonstrate that miR-431, which is up-regulated by HuIFN-β in RSa cells, suppresses the IGF1R signaling pathway. Delivery of miR-431 and a PI3K inhibitor in a combination therapeutic approach may represent an effective strategy for the treatment of HuIFN-β resistant cancers. 
